

# B S R & Co. LLP

Chartered Accountants

Building No.10, 8th Floor, Tower-B  
DLF Cyber City, Phase - II  
Gurugram - 122 002, India

Telephone: + 91 124 719 1000  
Fax: + 91 124 235 8613

## Limited review report on quarterly Consolidated Unaudited Results pursuant to Regulation 33 of the Listing Regulations

To  
Board of Directors of Jubilant Life Sciences Limited

We have reviewed the accompanying Statement of Consolidated Unaudited Results ('the consolidated financial results') of Jubilant Life Sciences Limited ('the Company') and its subsidiaries (collectively referred to as 'the Group') for the quarter ended 30 June 2018, attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations'). Attention is drawn to the fact that the figures for the 3 months ended 31 March 2018 as reported in these consolidated financial results are the balancing figures between audited figures in respect of the full previous financial year and the published year to date figures up to the third quarter of the previous financial year. The figures up to the end of the third quarter of previous financial year had only been reviewed and not subjected to audit.

These consolidated financial results are the responsibility of the Company's Management and has been approved by the Board of Directors on 27 July 2018. Our responsibility is to issue a report on these consolidated financial results based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, *Review of Interim Financial Information Performed by the Independent Auditor of the Entity* specified under section 143(10) of the Companies Act, 2013. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the consolidated financial results are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

The consolidated financial results includes the following entities:

1. Jubilant Pharma Limited
2. Draximage Limited, Cyprus
3. Draximage Limited, Ireland
4. Jubilant Draximage (USA) Inc.
5. Jubilant Draximage Inc.
6. 6963196 Canada Inc. (merged into 6981364 Canada Inc. w.e.f 1 April 2018)
7. 6981364 Canada Inc.
8. Draximage (UK) Limited
9. Jubilant Pharma Holdings Inc.
10. Jubilant Clinsys Inc.
11. Cadista Holdings Inc.
12. Jubilant Cadista Pharmaceuticals Inc.
13. Jubilant Life Sciences International Pte. Limited
14. HSL Holdings Inc.
15. Jubilant HollisterStier LLC
16. Jubilant Life Sciences (Shanghai) Limited

17. Jubilant Pharma NV
18. Jubilant Pharmaceuticals NV
19. PSI Supply NV
20. Jubilant Life Sciences (USA) Inc.
21. Jubilant Life Sciences (BVI) Limited
22. Jubilant Biosys (BVI) Limited
23. Jubilant Biosys (Singapore) Pte. Limited
24. Jubilant Biosys Limited
25. Jubilant Discovery Services LLC
26. Jubilant Drug Development Pte. Limited
27. Jubilant Chemsys Limited
28. Jubilant Clinsys Limited
29. Jubilant Infrastructure Limited
30. Jubilant First Trust Healthcare Limited
31. Jubilant Pharma Trading Inc.
32. Jubilant Innovation Pte. Limited
33. Jubilant Draximage Limited
34. Jubilant Innovation (India) Limited
35. Jubilant Innovation (USA) Inc.
36. Jubilant HollisterStier Inc.
37. Draxis Pharma LLC
38. Drug Discovery and Development Solutions Limited
39. Jubilant Drug Discovery & Development Services Inc.
40. Jubilant HollisterStier General Partnership
41. Draximage General Partnership
42. Vanthys Pharmaceutical Development Private Limited
43. Jubilant Generics Limited
44. Jubilant Life Sciences NV
45. Jubilant Pharma Australia Pty Limited
46. Jubilant Draximage Radiopharmacies Inc.
47. Jubilant Employee Welfare Trust

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying consolidated financial results, prepared in accordance with applicable accounting standards i.e. Ind AS prescribed under Section 133 of the Companies Act, 2013 and other recognised accounting practices and policies, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations including the manner in which it is to be disclosed, or that it contains any material misstatement.

**For B S R & Co. LLP**

*Chartered Accountants*

ICAI Firm's Registration No. 101248W/W-100022



**Pravin Tulsyan**

*Partner*

Membership No. 108044

Place: Noida

Date: 27 July 2018

# Jubilant Life Sciences Limited

Regd. Office: Bhartiagram, Gajraula, Distt. Amroha-244 223 (U.P.)

CIN:L24116UP1978PLC004624

Website: www.jubl.com, Email: investors@jubl.com, Tel: +91-5924-252353-60, Fax: +91-5924-252352

## Statement of Consolidated Unaudited Results for the Quarter ended 30 June 2018

Sr. No.	Particulars	Quarter Ended			(₹ in Lakhs)
		30 June	31 March	30 June	Year Ended
		(Unaudited)	(Audited)	(Unaudited)	(Audited)
		2018	2018	2017	2018
1	<b>Revenue from operations</b>				
	a) Sales/Income from operations (Refer note 3 below)	204629	222377	157813	746475
	b) Other operating income	3236	2819	1792	9306
	<b>Total revenue from operations</b>	<b>207865</b>	<b>225196</b>	<b>159605</b>	<b>755781</b>
2	Other income	947	2291	681	4003
3	<b>Total income (1+2)</b>	<b>208812</b>	<b>227487</b>	<b>160286</b>	<b>759784</b>
4	<b>Expenses</b>				
	a) Cost of materials consumed	78239	78119	54938	267815
	b) Purchases of stock-in-trade	5911	7344	3822	24282
	c) Changes in inventories of finished goods, stock-in-trade and work-in progress	(4526)	3619	(405)	(5220)
	d) Excise duty on sales	-	-	3975	3997
	e) Employee benefits expense	45158	45383	31032	155588
	f) Finance costs (Refer note 6 below)	7270	7248	6873	28428
	g) Depreciation and amortization expense (Refer note 9 below)	8800	18174	7248	41505
	h) Other expenses:				
	- Power and fuel expense	9970	11187	9046	42491
	- Others	29353	33757	23436	114990
	<b>Total expenses</b>	<b>180175</b>	<b>204831</b>	<b>139965</b>	<b>673876</b>
5	<b>Profit before exceptional items and tax (3-4)</b>	<b>28637</b>	<b>22656</b>	<b>20321</b>	<b>85908</b>
6	Exceptional items	-	-	-	-
7	<b>Profit before tax (5-6)</b>	<b>28637</b>	<b>22656</b>	<b>20321</b>	<b>85908</b>
8	Tax expense	8600	7416	5950	22466
9	<b>Net Profit for the period (7-8)</b>	<b>20037</b>	<b>15240</b>	<b>14371</b>	<b>63442</b>
10	<b>Other Comprehensive Income (OCI)</b>				
	i) a) Items that will not be reclassified to profit or loss	(127)	82	(264)	(358)
	b) Income tax relating to items that will not be reclassified to profit or loss	22	49	33	158
	ii) a) Items that will be reclassified to profit or loss	1470	(1463)	4178	6739
	b) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-
11	<b>Total Comprehensive Income for the period (9+10)</b>	<b>21402</b>	<b>13908</b>	<b>18318</b>	<b>69981</b>
	<b>Net Profit attributable to:</b>				
	Owners of the Company	20250	15487	14714	64281
	Non-controlling Interest	(213)	(247)	(343)	(839)
	<b>Other Comprehensive Income attributable to:</b>				
	Owners of the Company	1366	(1334)	3949	6540
	Non-controlling Interest	(1)	2	(2)	(1)
	<b>Total Comprehensive Income attributable to:</b>				
	Owners of the Company	21616	14153	18663	70821
	Non-controlling Interest	(214)	(245)	(345)	(840)
12	Earnings per share of ₹ 1 each (not annualized)				
	<b>Basic (₹)</b>	13.00	9.94	9.44	41.25
	<b>Diluted (₹)</b>	13.00	9.94	9.44	41.25
13	Paid-up equity share capital (Face value per share ₹ 1)	1558	1558	1557	1558
14	Reserves excluding Revaluation Reserves				407095
	<b>See accompanying notes to the Consolidated Unaudited Results</b>				

# Jubilant Life Sciences Limited

Note1: Consolidated Unaudited Segment wise Revenue, Results, Assets, Liabilities and Capital Employed for the Quarter ended 30 June 2018

Sr. No.	Particulars	Quarter Ended			(₹ in Lakhs)
		30 June	31 March	30 June	Year Ended
		(Unaudited)	(Audited)	(Unaudited)	(Audited)
		2018	2018	2017	2018
1	Segment revenue				
	a. Pharmaceuticals	118126	123326	81382	399889
	b. Life Sciences Ingredients	84927	96981	73832	337239
	c. Others	5079	5142	4535	19513
	<b>Total</b>	<b>208132</b>	<b>225449</b>	<b>159749</b>	<b>756641</b>
	Less : Inter segment revenue	267	253	144	860
	<b>Total revenue from operations</b>	<b>207865</b>	<b>225196</b>	<b>159605</b>	<b>755781</b>
	a. Pharmaceuticals	118126	123326	81382	399871
	b. Life Sciences Ingredients	84684	96751	73688	336489
	c. Others	5055	5119	4535	19421
	<b>Total</b>	<b>207865</b>	<b>225196</b>	<b>159605</b>	<b>755781</b>
2	Segment results (profit(+)/loss(-) before tax, exceptional items and Interest from each segment)				
	a. Pharmaceuticals	27871	14700	21344	68934
	b. Life Sciences Ingredients	8772	16589	8765	54814
	c. Others	44	250	(1122)	(1964)
	<b>Total</b>	<b>36687</b>	<b>31539</b>	<b>28987</b>	<b>121784</b>
	Less : i Interest (Finance costs)	7270	7248	6873	28428
	ii. Exceptional items and un-allocable expenditure (net of un-allocable income)	780	1635	1793	7448
	<b>Profit before tax</b>	<b>28637</b>	<b>22656</b>	<b>20321</b>	<b>85908</b>
3	Segment assets				
	a. Pharmaceuticals	642148	616205	589533	616205
	b. Life Sciences Ingredients	295794	293088	262755	293088
	c. Others	17583	16817	18762	16817
	d. Unallocable corporate assets (excluding deferred tax assets)	20814	19607	25809	19607
	<b>Total Segment assets</b>	<b>976339</b>	<b>945717</b>	<b>896859</b>	<b>945717</b>
4	Segment liabilities				
	a. Pharmaceuticals	61436	62176	48228	62176
	b. Life Sciences Ingredients	76683	86811	63579	86811
	c. Others	4463	4230	3920	4230
	d. Unallocable corporate liabilities (excluding borrowings and deferred tax liabilities)	41053	41849	31481	41849
	<b>Total Segment liabilities</b>	<b>183635</b>	<b>195066</b>	<b>147208</b>	<b>195066</b>
5	Capital employed (Segment assets less Segment liabilities)				
	a. Pharmaceuticals	580712	554029	541305	554029
	b. Life Sciences Ingredients	219111	206277	199176	206277
	c. Others	13120	12587	14842	12587
	d. Unallocable corporate assets less liabilities	(20239)	(22242)	(5672)	(22242)
	<b>Total Capital employed</b>	<b>792704</b>	<b>750651</b>	<b>749651</b>	<b>750651</b>



9/

2. The Company has opted to publish consolidated results for the year ending 31 March 2019. The standalone unaudited results are available under Investors section of our website at [www.jubl.com](http://www.jubl.com) and under Financial Results at Corporates section of [www.nseindia.com](http://www.nseindia.com) and [www.bseindia.com](http://www.bseindia.com). Key standalone financial information of the Company is as under:

Particulars	Quarter Ended			(₹ in Lakhs)
	30 June	31 March	30 June	31 March
	(Unaudited)	(Audited)	(Unaudited)	(Audited)
	2018	2018	2017	2018
Total revenue from operations	82664	96443	71027	334301
Profit before tax	3345	11878	2741	36769
Net profit after tax	2388	8639	2229	26344

3. Sales/Income from operations for the current quarter and immediately preceding quarter is not comparable with previous periods since the same is net of Goods and Services Tax (GST) whereas excise duty formed part of expenses till 30 June 2017.

4. The Secured Rated Listed Redeemable Non-Convertible Debentures (NCDs) aggregating to ₹ 49500 lakhs outstanding as at 30 June 2018 are secured by a first pari-passu charge by way of mortgage on certain immovable assets and entire movable fixed assets, both present and future, of the Company. The asset cover thereof based on agreed methodology exceeds 100% of the outstanding principal amount of the said NCDs.

5. The board has taken on record resolution passed at the board meeting of one of its material subsidiary company Jubilant Pharma Limited (JPL) to evaluate fund raising opportunity through IPO which could result in dilution of company's stake in the subsidiary.

6. Finance costs for the quarters ended 30 June 2018, 31 March 2018, 30 June 2017 and year ended 31 March 2018 include ₹ 2189 lakhs, ₹ 2057 lakhs, ₹ 1397 lakhs and ₹ 6448 lakhs, respectively, towards charge on outstanding zero coupon financing of US\$ 58.2 million from International Finance Corporation in JPL.

7. Effective 1 April 2018, the Company has realigned its segment to report its Indian Branded Pharmaceuticals and Drug Discovery Solutions businesses as Others. Hence, numbers for the previous periods have been regrouped to conform to current period reporting.

8. Effective 1 April 2018, the Group adopted Ind AS 115 "Revenue from Contracts with Customers" using the cumulative effect method which is applied to contracts that were not completed as of 1 April 2018. Accordingly, the comparatives have not been retrospectively adjusted. There is no material effect on adoption of Ind AS 115 on the consolidated unaudited results.

9. Depreciation and amortization expense for the quarter and year ended 31 March 2018 includes ₹ 9102 lakhs representing one time charge of product development expenses due to rationalization of product portfolio to reflect the current market conditions prevailing in the global generic markets, US in particular.

10. The above consolidated unaudited results were reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on 27 July 2018. The figures for the preceding quarter ended 31 March 2018, as reported in these consolidated financial results, are the balancing figures between audited figures in respect of the full financial year ended 31 March 2018 and the published year to date figures upto the end of third quarter of that financial year. Also, the figures upto the end of the third quarter had only been reviewed and not subjected to audit. The review report of the Statutory Auditors is being filed with the BSE and National Stock Exchange. For more details on consolidated unaudited results, visit Investors section of our website at [www.jubl.com](http://www.jubl.com) and Financial Results at Corporates section of [www.nseindia.com](http://www.nseindia.com) and [www.bseindia.com](http://www.bseindia.com).

For Jubilant Life Sciences Limited



Hari S. Bhartia  
Co-Chairman & Managing Director

Place : Noida  
Date : 27 July 2018

